Heart Amyloid Deposits Studied in People With Alzheimer's Disease

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who are already having a brain amyloid PET scan to check for Alzheimer's disease. They also get a heart PET/MRI scan, an echocardiogram and a dementia examination.

Age

18 years or older

Sex

All sexes can join.

Disease stage

People having a brain amyloid PET scan for a clinical reason, to clarify Alzheimer's disease.

Main reasons for not taking part

• Cannot have an MRI scan
• Cannot have an amyloid PET scan
• Vascular dementia or another confirmed cause of dementia, such as stroke, vitamin deficiency, thyroid insufficiency or alcohol
• Pronounced heart conditions
• Pregnant or breastfeeding women

The registry criteria, word for word

What the trial wants to find out

This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.

The group in the trial

• Patients referred for cerebral amyloid PET to clarify Alzheimer's disease

  The study population consists of patients who have been clinically referred for a cerebral amyloid PET examination to clarify a diagnosis of Alzheimer's disease. The study population will undergo a comprehensive diagnostic evaluation, which includes: * An extension of the amyloid PET examination to include cardiac PET/MRI imaging. No additional substances are applied and there is no additional radiation exposure. * A transthoracic echocardiogram, including strain analysis * A 12-lead electrocardiogram (EKG)